A groundbreaking study has unveiled the potential of a natural psychoactive compound, DMT (N, N-dimethyltryptamine), in mitigating the devastating consequences of stroke. This molecule, found in various plants and animals, including the human brain, is currently under investigation in human clinical trials for its ability to aid in the recovery of brain function following a stroke event. The findings from researchers at the HUN-REN BRC Institute of Biophysics and Semmelweis University Heart and Vascular Centre suggest a novel approach to stroke therapy by targeting both the blood-brain barrier and neuroinflammation.
Breakthrough Research: DMT's Therapeutic Potential in Stroke Recovery
In a significant scientific development, a team of researchers from the HUN-REN BRC Institute of Biophysics and Semmelweis University Heart and Vascular Centre, located in Szeged and Budapest, Hungary, has shed new light on the therapeutic capabilities of N, N-dimethyltryptamine (DMT). Their collaborative work, published in the esteemed journal Science Advances on September 26, 2025, details how this naturally occurring psychoactive molecule can substantially reduce the detrimental impacts of stroke in preclinical models. Co-lead author M\u00e1ria Deli from HUN-REN BRC emphasized nature's remarkable ability to provide solutions for complex health issues, highlighting DMT as a prime example. The study, spearheaded by co-first author Marcell L\u00e1szl\u00f3, demonstrated that DMT therapy led to a significant reduction in infarct volume and edema formation in a rat model of stroke. Furthermore, both animal experiments and cell culture investigations revealed that DMT treatment successfully reinstated the integrity and functionality of the compromised blood-brain barrier and enhanced the performance of astroglial cells. The psychoactive compound also exhibited anti-inflammatory properties by inhibiting the production of inflammatory cytokines in brain endothelial cells and peripheral immune cells, while simultaneously decreasing the activation of brain microglia cells through Sigma-1 receptors. Judit Vigh, also a co-first author, underscored the critical need for improved stroke treatments, stating, \"The dual action of DMT, protecting the blood-brain barrier while reducing brain inflammation, offers a novel, complex approach that could complement existing treatments.\" This research marks a pivotal step toward developing DMT-based therapies that could overcome the current limitations of conventional stroke treatment, with ongoing clinical trials exploring its long-term effects.
This research offers a beacon of hope for stroke patients worldwide. The current therapeutic landscape for stroke is often limited, leaving many individuals with significant long-term disabilities. The dual protective mechanism of DMT\u2014restoring the blood-brain barrier and combating inflammation\u2014presents a sophisticated and comprehensive strategy. If these promising preclinical results translate effectively into human clinical trials, DMT could revolutionize stroke care, offering a much-needed adjunctive therapy that not only improves immediate outcomes but also enhances the quality of life for survivors.
